SCHEMBL1748716

SCHEMBL1748716

COc1cc2c(-c3cc4cc(F)cnc4[nH]3)cn(CCN3CCN(C)CC3)c2cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.46
FGFR3 P22607 1/20 0.36
VCP P55072 1/20 0.36
MAP4K1 Q92918 1/20 0.35
CDK9 P50750 5/20 0.35
GSK3B P49841 4/20 0.35
FGFR1 P11362 3/20 0.35
KDR P35968 3/20 0.35
AURKA O14965 2/20 0.35
PAK4 O96013 2/20 0.35
ABL1 P00519 2/20 0.35
NTRK1 P04629 2/20 0.35
LCK P06239 2/20 0.35
FYN P06241 2/20 0.35
CSF1R P07333 2/20 0.35
RET P07949 2/20 0.35
MET P08581 2/20 0.35
PDGFRB P09619 2/20 0.35
PIM1 P11309 2/20 0.35
PRKACA P17612 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748831 0.92 IGF1R (0.46) IGF1RCDK9GSK3BKDRKDM4E
SCHEMBL1749006 0.84 IGF1R (0.67) IGF1RGSK3BKDRLCKRET
SCHEMBL1748413 0.81 IGF1R (0.63) IGF1RGSK3BKDRFLT3CLK2
SCHEMBL1748861 0.81 IGF1R (0.67) IGF1RCDK9GSK3BFGFR1KDR
SCHEMBL2991422 0.80 CDK9 (0.39) IGF1RCDK9GSK3BKDRKDM4E
SCHEMBL27668977 0.79 IGF1R (0.59) IGF1RCDK9AURKAKDM4EALDH1A1
SCHEMBL5794491 0.79 GSK3B (0.39) IGF1RGSK3BKDRFLT3KDM4E
SCHEMBL1748870 0.78 IGF1R (0.46) IGF1RCDK9GSK3BKDRLCK
SCHEMBL1748897 0.78 IGF1R (0.65) IGF1RMAP4K1CDK9GSK3BLCK
SCHEMBL1748879 0.77 IGF1R (0.61) IGF1RGSK3BKDRCLK2SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US claimed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US claimed
US-7968566-B2 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-06-28 US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885FGFR3 756/4885VCP 3961/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885FGFR3 756/4885VCP 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.